Metraipolis › archive › dc_df8277dde724
Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA — Europe PMC PMID:34964438
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/34964438
- DOI
- 10.7554/elife.70472
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-31T19:39:20.067Z
- SHA-256 of the archived text
63be80f6b62b82dd7ab504ff59f638fb5e496ec1f57f475d2b22f237bca85a56- Stable URL of this page
https://metraipolis.com/documento/dc_df8277dde724
How to cite
Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA — Europe PMC PMID:34964438 — Europe PMC (en), https://europepmc.org/article/MED/34964438 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_df8277dde724 (Metraipolis archive dc_df8277dde724, sha256 63be80f6b62b82dd7ab504ff59f638fb5e496ec1f57f475d2b22f237bca85a56)
BibTeX
@misc{dcdf8277dde724,
title = {Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA — Europe PMC PMID:34964438},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/34964438},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_df8277dde724; sha256 63be80f6b62b82dd7ab504ff59f638fb5e496ec1f57f475d2b22f237bca85a56},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34964438. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive lipid accumulation and imbalances in lipid metabolism in the liver. Although nuclear receptors (NRs) play a crucial role in hepatic lipid metabolism, the underlying mechanisms of NR regulation in NAFLD remain largely unclear. Methods: Using network analysis and RNA-seq to determine the correlation between NRs and microRNA in human NAFLD patients, we revealed that MIR20B specifically targets PPARA. MIR20B mimic and anti- MIR20B were administered to human HepG2 and Huh-7 cells and mouse primary hepatocytes as well as high-fat diet (HFD)- or methionine-deficient diet (MCD)-fed mice to verify the specific function of MIR20B in NAFLD. We tested the inhibition of the therapeutic effect of a PPARα agonist, fenofibrate, by Mir20b and the synergic effect of combination of fenofibrate with anti- Mir20b in NAFLD mouse model. Results: We revealed that MIR20B specifically targets PPARA through miRNA regulatory network analysis of nuclear receptor genes in NAFLD. The expression of MIR20B was upregulated in free fatty acid (FA)-treated hepatocytes and the livers of both obesity-induced mice and NAFLD patients. Overexpression of MIR20B significantly increased hepatic lipid accumulation and triglyceride levels. Furthermore, MIR20B significantly reduced FA oxidation and mitochondrial biogenesis by targeting PPARA . In Mir20b -introduced mice, the effect of fenofibrate to ameliorate hepatic steatosis was significantly suppressed. Finally, inhibition of Mir20b significantly increased FA oxidation and uptake, resulting in improved insulin sensitivity and a decrease in NAFLD progression. Moreover, combination of fenofibrate and anti- Mir20b exhibited the synergic effect on improvement of NAFLD in MCD-fed mice. Conclusions: Taken together, our results demonstrate that the novel MIR20B targets PPARA , plays a significant role in hepatic lipid metabolism, and present an opportunity for the development of novel therapeutics for NAFLD. Funding: This research was funded by Korea Mouse Phenotyping Project (2016M3A9D5A01952411), the National Research Foundation of Korea (NRF) grant funded by the Korea government (2020R1F1A1061267, 2018R1A5A1024340, NRF-2021R1I1A2041463, 2020R1I1A1A01074940, 2016M3C9A394589324), and the Future-leading Project Research Fund (1.210034.01) of UNIST. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: eLife, 2021 (prima pubblicazione 2021-12-29). Identificativi: PMID 34964438 · PMCID PMC8758141 · DOI 10.7554/elife.70472. Parole chiave degli autori: Human; Cell biology; Mouse; Medicine; Combination therapy; Nafld; Pparα; Mir-20b. Descrittori MeSH principali: Lipid Metabolism. Pagina: https://europepmc.org/article/MED/34964438 — https://doi.org/10.7554/elife.70472. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-31T19:31:24.209Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.